» Articles » PMID: 38710699

De Novo Generation of Multi-target Compounds Using Deep Generative Chemistry

Overview
Journal Nat Commun
Specialty Biology
Date 2024 May 6
PMID 38710699
Authors
Affiliations
Soon will be listed here.
Abstract

Polypharmacology drugs-compounds that inhibit multiple proteins-have many applications but are difficult to design. To address this challenge we have developed POLYGON, an approach to polypharmacology based on generative reinforcement learning. POLYGON embeds chemical space and iteratively samples it to generate new molecular structures; these are rewarded by the predicted ability to inhibit each of two protein targets and by drug-likeness and ease-of-synthesis. In binding data for >100,000 compounds, POLYGON correctly recognizes polypharmacology interactions with 82.5% accuracy. We subsequently generate de-novo compounds targeting ten pairs of proteins with documented co-dependency. Docking analysis indicates that top structures bind their two targets with low free energies and similar 3D orientations to canonical single-protein inhibitors. We synthesize 32 compounds targeting MEK1 and mTOR, with most yielding >50% reduction in each protein activity and in cell viability when dosed at 1-10 μM. These results support the potential of generative modeling for polypharmacology.

Citing Articles

Foundation models in bioinformatics.

Guo F, Guan R, Li Y, Liu Q, Wang X, Yang C Natl Sci Rev. 2025; 12(4):nwaf028.

PMID: 40078374 PMC: 11900445. DOI: 10.1093/nsr/nwaf028.


Hallmarks of artificial intelligence contributions to precision oncology.

Chang T, Park S, Schaffer A, Jiang P, Ruppin E Nat Cancer. 2025; .

PMID: 40055572 DOI: 10.1038/s43018-025-00917-2.


Knowledge-guided diffusion model for 3D ligand-pharmacophore mapping.

Yu J, Zhou C, Ning X, Mou J, Meng F, Wu J Nat Commun. 2025; 16(1):2269.

PMID: 40050649 PMC: 11885826. DOI: 10.1038/s41467-025-57485-3.


Design of Supported Ionic Liquid Membranes for CO Capture Using a Generative AI-Based Approach.

Ismail S, Safari H, Bavarian M Ind Eng Chem Res. 2025; 64(8):4439-4449.

PMID: 40026352 PMC: 11869161. DOI: 10.1021/acs.iecr.4c03280.


The physics-AI dialogue in drug design.

Vargas-Rosales P, Caflisch A RSC Med Chem. 2025; .

PMID: 39906313 PMC: 11788922. DOI: 10.1039/d4md00869c.


References
1.
Cichonska A, Ravikumar B, Allaway R, Wan F, Park S, Isayev O . Crowdsourced mapping of unexplored target space of kinase inhibitors. Nat Commun. 2021; 12(1):3307. PMC: 8175708. DOI: 10.1038/s41467-021-23165-1. View

2.
Santarpia L, Lippman S, El-Naggar A . Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1):103-19. PMC: 3457779. DOI: 10.1517/14728222.2011.645805. View

3.
Knight Z, Lin H, Shokat K . Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010; 10(2):130-7. PMC: 2880454. DOI: 10.1038/nrc2787. View

4.
Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

5.
ONeil J, Benita Y, Feldman I, Chenard M, Roberts B, Liu Y . An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. Mol Cancer Ther. 2016; 15(6):1155-62. DOI: 10.1158/1535-7163.MCT-15-0843. View